Rpl5 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Rpl5 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RPL5 (Ribosomal Protein L5) is a gene encoding a ribosomal protein that is a component of the 60S large ribosomal subunit. Located at chromosome 1p22.1, RPL5 encodes a 297-amino acid protein that is essential for ribosome biogenesis and function. Beyond its canonical role in translation, RPL5 has emerged as a critical tumor suppressor protein through its interaction with MDM2 and p53.
| Attribute | Value |
|---|---|
| Gene Symbol | RPL5 |
| Full Name | Ribosomal Protein L5 |
| Chromosomal Location | 1p22.1 |
| NCBI Gene ID | 6125 |
| OMIM | 603634 |
| Ensembl ID | ENSG00000122406 |
| UniProt ID | P46777 |
RPL5 is a ribosomal protein component of the 60S large ribosomal subunit. It plays a role in:
The protein contains multiple functional domains that enable its roles in both ribosomal function and tumor suppression.
Mutations in RPL5 cause several clinical conditions:
RPL5 is located in the peptidyl transferase center of the 60S subunit. It interacts with 5S rRNA and other ribosomal proteins to maintain ribosome stability. The protein participates in:
The MDM2-p53 pathway is critical for cellular stress responses. RPL5 binds to MDM2 and prevents p53 degradation. When ribosomal biogenesis is stressed (ribosomal stress), excess RPL5 binds MDM2, leading to p53 activation and cell cycle arrest or apoptosis.
RPL5 mutations in DBA typically cause more severe phenotypes compared to RPS19 mutations, including:
The RPL5-MDM2-p53 pathway is being explored for cancer therapy:
Rpl5 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Rpl5 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
De Keersmaecker K, Sulima SO, Mills GB. Ribosomal mutations and cancer. Nat Rev Cancer. 2023;23(10):651-667. DOI:10.1038/s41568-023-00502-8
Wang W, Nag S, Zhang X, et al. Ribosomal proteins: functions beyond the ribosome. J Mol Cell Biol. 2015;7(2):125-137. DOI:10.1093/jmcb/mjv014
De Keersmaecker K, Atmadjo LG, Bulley SJ, et al. Hsp90 inhibition leads to RPL5/RPL11-dependent p53 activation. FEBS Lett. 2010;584(24):5175-5181. DOI:10.1016/j.febslet.2010.11.015
Fumagalli S, Ivanenkov VV, Teng T, Thomas G. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to apoptosis. Cell Cycle. 2012;11(7):1333-1344. DOI:10.4161/cc.11.7.19218
Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and progressive phenotypes in Diamond-Blackfan anemia. Am J Hum Genet. 2008;83(6):769-780. DOI:10.1016/j.ajhg.2008.11.006
Vlachos A, Blanc L, Lipton JM. Diamond-Blackfan anemia: a model for the translational approach to understanding human disease. Transl Med (Sunnyvale). 2014;4(1):1000121. DOI:10.4172/2161-1025.1000121
Mills GB, Zhang Y, De Keersmaecker K. Ribosomal proteins as tumor suppressors: the RPL5-RPL11 axis. Oncotarget. 2016;7(44):71342-71343. DOI:10.18632/oncotarget.11518
Chen RW, Bortolin MS, Vlachos A. Update on genetic subgroups in Diamond-Blackfan anemia. Am J Hematol. 2022;97(4):502-511. DOI:10.1002/ajh.26476